304 related articles for article (PubMed ID: 38500508)
1. Identifying potential monkeypox virus inhibitors: an
Ashley CN; Broni E; Wood CM; Okuneye T; Ojukwu MT; Dong Q; Gallagher C; Miller WA
Front Cell Infect Microbiol; 2024; 14():1351737. PubMed ID: 38500508
[TBL] [Abstract][Full Text] [Related]
2. Identification of Antiviral Compounds against Monkeypox Virus Profilin-like Protein A42R from
Bajrai LH; Alharbi AS; El-Day MM; Bafaraj AG; Dwivedi VD; Azhar EI
Molecules; 2022 Nov; 27(22):. PubMed ID: 36431817
[TBL] [Abstract][Full Text] [Related]
3. Structure of the Monkeypox virus profilin-like protein A42R reveals potential functional differences from cellular profilins.
Minasov G; Inniss NL; Shuvalova L; Anderson WF; Satchell KJF
Acta Crystallogr F Struct Biol Commun; 2022 Oct; 78(Pt 10):371-377. PubMed ID: 36189721
[TBL] [Abstract][Full Text] [Related]
4. Identification of
Chiem K; Nogales A; Lorenzo M; Morales Vasquez D; Xiang Y; Gupta YK; Blasco R; de la Torre JC; Martínez-Sobrido L
Microbiol Spectr; 2023 Aug; 11(4):e0474522. PubMed ID: 37278625
[TBL] [Abstract][Full Text] [Related]
5. Potential Inhibitors of Monkeypox Virus Revealed by Molecular Modeling Approach to Viral DNA Topoisomerase I.
Hu X; An S; Chu J; Liang B; Liao Y; Jiang J; Lin Y; Ye L; Liang H
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771105
[TBL] [Abstract][Full Text] [Related]
6. Antivirals against monkeypox infections.
Chiem K; Nogales A; Lorenzo M; Vasquez DM; Xiang Y; Gupta YK; Blasco R; de la Torre JC; Mart Nez-Sobrido L
bioRxiv; 2023 Apr; ():. PubMed ID: 37131608
[TBL] [Abstract][Full Text] [Related]
7. Supervised screening of Tecovirimat-like compounds as potential inhibitors for the monkeypox virus E8L protein.
Mehmood A; Nawab S; Jia G; Kaushik AC; Wei DQ
J Biomol Struct Dyn; 2023 Aug; ():1-14. PubMed ID: 37561169
[TBL] [Abstract][Full Text] [Related]
8. Screening of potential inhibitors against structural proteins from Monkeypox and related viruses of
Kaur M; Sharma A; Kaur H; Singh M; Devi B; Naresh Raj AR; Sood V; Pandey A; Gartia J; Kumar R; Suresh Babu AR; Singh G; Barnwal RP
J Biomol Struct Dyn; 2023 Sep; ():1-16. PubMed ID: 37776002
[TBL] [Abstract][Full Text] [Related]
9. Fragment-Based Approaches Identified Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13 Protein of the Monkeypox Virus.
Ali Y; Imtiaz H; Tahir MM; Gul F; Saddozai UAK; Ur Rehman A; Ren ZG; Khattak S; Ji XY
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851785
[TBL] [Abstract][Full Text] [Related]
10. Exploration of Microbially Derived Natural Compounds against Monkeypox Virus as Viral Core Cysteine Proteinase Inhibitors.
Dubey A; Alawi MM; Alandijany TA; Alsaady IM; Altwaim SA; Sahoo AK; Dwivedi VD; Azhar EI
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680291
[TBL] [Abstract][Full Text] [Related]
11. Proteome-Based Investigation Identified Potential Drug Repurposable Small Molecules Against Monkeypox Disease.
Bhattacharjee A; Ahammad I; Chowdhury ZM; Das KC; Keya CA; Salimullah M
Mol Biotechnol; 2024 Apr; 66(4):626-640. PubMed ID: 36357534
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of eighteen clinical isolates of human monkeypox virus to tecovirimat.
Nunes DDS; Higa LM; Oliveira RL; da Costa LC; Bomfim LM; Gonçalves CCA; Mariani D; Hruby DE; Voloch CM; Castiñeiras TMPP; Tanuri A; Damaso CR
Mem Inst Oswaldo Cruz; 2023; 118():e230056. PubMed ID: 37436275
[TBL] [Abstract][Full Text] [Related]
13. Machine learning and classical MD simulation to identify inhibitors against the P37 envelope protein of monkeypox virus.
Rout M; Dey S; Mishra S; Panda S; Singh MK; Sinha R; Dehury B; Pati S
J Biomol Struct Dyn; 2024 May; 42(8):3935-3948. PubMed ID: 37221882
[TBL] [Abstract][Full Text] [Related]
14. Computational Repurposing of Mitoxantrone-Related Structures against Monkeypox Virus: A Molecular Docking and 3D Pharmacophore Study.
Preet G; Oluwabusola ET; Milne BF; Ebel R; Jaspars M
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430762
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic targets for Mpox: the evidence to date.
Byrareddy SN; Sharma K; Sachdev S; Reddy AS; Acharya A; Klaustermeier KM; Lorson CL; Singh K
Expert Opin Ther Targets; 2023; 27(6):419-431. PubMed ID: 37368464
[TBL] [Abstract][Full Text] [Related]
17. Tecovirimat Resistance in Mpox Patients, United States, 2022-2023.
Smith TG; Gigante CM; Wynn NT; Matheny A; Davidson W; Yang Y; Condori RE; O'Connell K; Kovar L; Williams TL; Yu YC; Petersen BW; Baird N; Lowe D; Li Y; Satheshkumar PS; Hutson CL
Emerg Infect Dis; 2023 Dec; 29(12):2426-2432. PubMed ID: 37856204
[TBL] [Abstract][Full Text] [Related]
18. Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24.
Kwofie SK; Broni E; Teye J; Quansah E; Issah I; Wilson MD; Miller WA; Tiburu EK; Bonney JHK
Comput Biol Med; 2019 Oct; 113():103414. PubMed ID: 31536833
[TBL] [Abstract][Full Text] [Related]
19. Identification of IMP Dehydrogenase as a Potential Target for Anti-Mpox Virus Agents.
Hishiki T; Morita T; Akazawa D; Ohashi H; Park ES; Kataoka M; Mifune J; Shionoya K; Tsuchimoto K; Ojima S; Azam AH; Nakajima S; Kawahara M; Yoshikawa T; Shimojima M; Kiga K; Maeda K; Suzuki T; Ebihara H; Takahashi Y; Watashi K
Microbiol Spectr; 2023 Aug; 11(4):e0056623. PubMed ID: 37409948
[TBL] [Abstract][Full Text] [Related]
20. Development of multi-epitope vaccines against the monkeypox virus based on envelope proteins using immunoinformatics approaches.
Tan C; Zhu F; Pan P; Wu A; Li C
Front Immunol; 2023; 14():1112816. PubMed ID: 36993967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
